Effects of Glucose Load and Nateglinide Intervention on Endothelial Function and Oxidative Stress

Table 5

Changes in FMEDD, NO, ET-1, MDA, and SOD in newly diagnosed type 2 diabetes after treatment with nateglinide.

Group		Before taking nateglinide	After taking nateglinide	Difference in levels before and after nateglinide treatment	P values ​ ​
Number of patients (M/F)		32 (19/13)	32 (19/13)
FMEDD	Fasting	12.20±3.21	16.06±4.23	3.86±4.11	<.001
	After glucose load	9.4±3.43	12.81±4.01	3.41±4.50	.0002
NO	Fasting	134.15±58.55	173.64±72.44	39.49±35.22	<.001*
	After glucose load	123.76±53.62	145.18±62.97	20.52±50.96	<0.001*
ET-1	Fasting	2.16±1.81	1.40±1.23	0.75±0.92	<.001*
	After glucose load	2.31±1.88	1.85±1.56	0.46±0.73	<.001*
MDA	Fasting	5.64±1.22	4.66±1.01	0.98±0.77	<.001*
	After glucose load	6.19±1.59	5.39±1.03	0.80±0.95	<.001*
SOD	Fasting	118.53±17.30	146.81±21.02	28.81±15.48	<.001
	After glucose load	99.84±17.09	125.28±16.58	25.44±13.00	.0002

FMEDD: flow-mediated endothelium-dependent dilation; NO: nitric oxide; ET-1: endothelin-1; MDA: malondialdehyde; SOD: superoxide dismutase.
*Using nonparametric analysis method.